BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol 2021:S1044-579X(21)00211-X. [PMID: 34324953 DOI: 10.1016/j.semcancer.2021.07.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Shkaraburov AS, Rudenko DN, Vaiman EF, Soboleva OM, Zakharova YV. Asymptomatic Hepatocellular Carcinoma (Clinical Case). Kreativnaâ hirurgiâ i onkologiâ 2022;12:256-260. [DOI: 10.24060/2076-3093-2022-12-3-256-260] [Reference Citation Analysis]
2 Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
3 Chen S, Duan H, Zhang D, Sun G, Li T. Correlation between RASSF1A Methylation in Cell-Free DNA and the Prognosis of Cancer Patients: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/3458420] [Reference Citation Analysis]
4 Luo J, Huang Z, Wang M, Li T, Huang J. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy. BMC Gastroenterol 2022;22:108. [PMID: 35260095 DOI: 10.1186/s12876-022-02129-9] [Reference Citation Analysis]
5 Wang J, Yang Z, Tang D, Han R, Bi Z, Lin L. GARS is implicated in poor survival and immune infiltration of hepatocellular carcinoma. Cell Signal 2022;:110302. [PMID: 35271987 DOI: 10.1016/j.cellsig.2022.110302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Habash NW, Sehrawat TS, Shah VH, Cao S. Epigenetics of Alcohol-Related Liver Diseases. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yan J, Huang QY, Huang YJ, Wang CS, Liu PX. SPATS2 is positively activated by long noncoding RNA SNHG5 via regulating DNMT3a expression to promote hepatocellular carcinoma progression. PLoS One 2022;17:e0262262. [PMID: 35077478 DOI: 10.1371/journal.pone.0262262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ganji C, Farran B. Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy. Drug Discov Today 2021:S1359-6446(21)00563-8. [PMID: 34952224 DOI: 10.1016/j.drudis.2021.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhu LR, Ni WJ, Cai M, Dai WT, Zhou H. Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies. Front Cell Dev Biol 2021;9:777007. [PMID: 34778277 DOI: 10.3389/fcell.2021.777007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]